Hanmi Pharmaceutical said on the 29th it unveiled preclinical results for a new anticancer drug, an "EP300 selective degrader," at an international cancer society academic meeting recently held in Boston. The technology selectively kills cancer cells that depend on the EP300 protein. It also presented an SOS1-KRAS interaction inhibitor, a STING messenger ribonucleic acid (mRNA) anticancer drug, a p53-mRNA anticancer drug, and a YAP/TAZ-TEAD inhibitor.
SK bioscience said on the 29th it discussed mid- to long-term cooperation plans with the Hallemann Institute, a global vaccine research organization. SK bioscience and the Hallemann Institute signed a joint development agreement in 2023 for a next-generation Zaire Ebola vaccine. Since then, they have been cooperating on vaccine candidate process development, technology transfer, and commercialization. They will develop next-generation vaccine platform technologies to respond to infectious diseases.
Chong Kun Dang said on the 29th it received approval from the European Medicines Agency (EMA) for a phase 1 clinical trial of CKD-704, a biosimilar psoriasis treatment. Chong Kun Dang plans to conduct the trial in Europe with more than 200 healthy adults. It aims to prove the equivalence of CKD-704 and Skyrizi (the original drug) and compare safety.
Myung In Pharm said on the 29th it will invest 130 billion won to expand the second Balan plant. The goal is to strengthen competitiveness in global contract development and manufacturing (CDMO). It will exclusively produce high value-added pellet formulations. Myung In Pharm is pursuing approval in 2026 for compliance with the Ministry of Food and Drug Safety's good manufacturing practice (GMP) standards, with the start of commercial production in 2027.
HLB PANAGENE subsidiary Biosquare said on the 29th it recently obtained export-only manufacturing approval from the Ministry of Food and Drug Safety for the in vitro diagnostic medical device "Nanopak HIV 1/2 Ab." It determines whether a person is infected with the human immunodeficiency virus (HIV). According to the World Health Organization (WHO), last year there were 40 million people with HIV, and 630,000 died from related diseases.
Kakao Healthcare said on the 29th it signed a supply contract with SkyLabs for the ring-type continuous blood pressure monitor "Cart BP." It will combine Kakao Healthcare's mobile and artificial intelligence (AI) technologies with SkyLabs' biosignal measurement technology. Kakao Healthcare plans to add a blood pressure management service within the year to its Pasta app, which enables health management on mobile with AI.
Cha&Mom said on the 29th it launched Happy Smile Kids toothpaste for children. Cha&Mom is the family health brand of Cha Bio F&C, an affiliate of the CHA Medical Group. It contains sodium fluoride, which is recognized in the United States as an ingredient for preventing cavities. A fermented lactic acid bacteria solution helps with oral care.
Samjin pharm said on the 29th it signed a business agreement with the Chungcheongbuk-do Sports Association for the Disabled to employ athletes with disabilities. Samjin pharm will gradually hire athletes with disabilities affiliated with North Chungcheong Province. It plans to support the athletes so they can continue training and participate in society.